Citation Impact
Citing Papers
Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor
1991 Standout
Parenteral Anticoagulants
2008
Parenteral Anticoagulants
2012 Standout
Heparin-Protein Interactions
2002 Standout
Structure and Biological Activity of Heparin
1985
A comparative study of the anti-inflammatory, anticoagulant, antiangiogenic, and antiadhesive activities of nine different fucoidans from brown seaweeds
2007 Standout
Prevention of Deep Vein Thrombosis after Elective Hip Surgery
1991
The Antithrombotic Activity and Pharmacokinetics of Enoxaparine, A Low Molecular Weight Heparin, In Humans Given Single Subcutaneous Doses of 20 to 80 mg
1988
Heparin and Low-Molecular-Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety
2001 Standout
Structure and Anticoagulant Activity of Sulfated Fucans
1999
Effect of pegylation on pharmaceuticals
2003 Standout
Nanoparticles in cancer therapy and diagnosis
2002 Standout
Delivery materials for siRNA therapeutics
2013 Standout
Subcutaneous Low-Molecular-Weight Heparin Compared with Continuous Intravenous Heparin in the Treatment of Proximal-Vein Thrombosis
1992 Standout
Isolation and characterization of heparan sulfate from crude porcine intestinal mucosal peptidoglycan heparin
1995
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
1996 Standout
Effect of PEO surface density on long-circulating PLA-PEO nanoparticles which are very low complement activators
1996
A Branched Monomethoxypoly(ethylene glycol) for Protein Modification
1995
Antithrombotic Therapy for VTE Disease
2012 Standout
Non-viral vectors for gene-based therapy
2014 Standout
Block copolymer micelles for drug delivery: design, characterization and biological significance
2001 Standout
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery
2015 Standout
Interactions of poly(lactic acid) and poly(lactic acid-co-ethylene oxide) nanoparticles with the plasma factors of the coagulation system
1997
Heparin and Low-Molecular-Weight Heparin
2004
Stealth Me. PEG‐PLA Nanoparticles Avoid Uptake by the Mononuclear Phagocytes System
1995
PLGA–mPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood properties
2002
Prevention of Venous Thromboembolism
2004 Standout
Heparin and Low-Molecular-Weight Heparin
1998
The Hazards of Scoring the Quality of Clinical Trials for Meta-analysis
1999 Standout
Development of sterically stabilized poly(isobutyl 2-cyanoacrylate) nanoparticles by chemical coupling of poly(ethylene glycol)
1997
Review: Multipoint binding and heterogeneity in immobilized metal affinity chromatography
1995 StandoutNobel
Selective cleavage and anticoagulant activity of a sulfated fucan: stereospecific removal of a 2-sulfate ester from the polysaccharide by mild acid hydrolysis, preparation of oligosaccharides, and heparin cofactor II–dependent anticoagulant activity
2004
Heparin-Induced Thrombocytopenia in Patients Treated with Low-Molecular-Weight Heparin or Unfractionated Heparin
1995 Standout
Multipoint binding in metal-affinity chromatography II. Effect of pH and imidazole on chromatographic retention of engineered histidine-containing cytochromes c
1996 StandoutNobel
Poly(ethylene glycol) in Drug Delivery: Pros and Cons as Well as Potential Alternatives
2010 Standout
PEG–Ara-C conjugates for controlled release
2004
Characterization of recombinant human .alpha.2-antiplasmin and of mutants obtained by site-directed mutagenesis of the reactive site
1987
Characterization of the heparin-binding site of glia-derived nexin/protease nexin-1
1992
Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: Results of a meta-analysis
1996
Heparin
1991
A Comparison of Low-Molecular-Weight Heparin with Unfractionated Heparin for Unstable Coronary Artery Disease
1997 Standout
Interaction of factor Xa with heparin does not contribute to the inhibition of factor Xa by antithrombin III-heparin
1990
Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis
1992
A Comparison of Enoxaparin with Placebo for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients
1999 Standout
Controlled Microwave Heating in Modern Organic Synthesis
2004 Standout
Organic Azides: An Exploding Diversity of a Unique Class of Compounds
2005 Standout
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo.
1991
Structure and Anticoagulant Activity of Sulfated Galactans
2000
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
2011 Standout
Glycosaminoglycans and the regulation of blood coagulation
1993
The antithrombin-binding sequence of heparin. Location of essential N-sulfate groups.
1981
The Binding of Low-Affinity and High-Affinity Heparin to Antithrombin. Fluorescence Studies
1978
Extracellular DNA traps promote thrombosis
2010 Standout
Impact of the patient population on the risk for heparin-induced thrombocytopenia
2000 Standout
BIOCHEMISTRY AND GENETICS OF VON WILLEBRAND FACTOR
1998 Standout
Surface Site Heterogeneity and Lateral Interactions in Multipoint Protein Adsorption
1996 StandoutNobel
Serpin Structure, Mechanism, and Function
2002 Standout
The effects of low molecular weight and standard heparin on calcium loss from fetal rat calvaria
1995
Binding of low-affinity and high-affinity heparin to antithrombin. Ultraviolet difference spectroscopy and circular dichroism studies
1978
Interactions among Heparin, Cold-Insoluble Globulin, and Fibrinogen in Formation of the Heparin-Precipitable Fraction of Plasma
1977
A Metal-Chelating Lipid for 2D Protein Crystallization via Coordination of Surface Histidines
1997 StandoutNobel
Energetics and Dynamics of Enzymatic Reactions
2001 StandoutNobel
Binding and two-dimensional crystallization of streptavidin at the air/water interface via engineered Cu-IDA chelator lipids
1999 StandoutNobel
Polymeric Systems for Controlled Drug Release
1999 Standout
The structure of heparin oligosaccharide fragments with high anti-(factor Xa) activity containing the minimal antithrombin III-binding sequence Chemical and13C nuclear-magnetic-resonance studies
1981
Microwave‐Assisted Synthesis of a Soluble Single Wall Carbon Nanotube Derivative
2003
Kinetics of intravenously administered heparin in normal humans
1982
Neutralization of heparin by histone and its subfractions
1983
Low molecular weight heparin (PK 10169) does not cross the placenta during the second trimester of pregnancy study by direct fetal blood sampling under ultrasound
1984
Nanoparticles in Photodynamic Therapy
2015 Standout
Guide to anticoagulant therapy. Part 1: Heparin. American Heart Association.
1994
Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin). Results of a double-blind randomized study.
1989
Anticoagulant and antithrombotic effects of heparin and low molecular weight heparin fragments in rabbits
1982
Effect of Heparin and Heparin Fractions on Platelet Aggregation
1980
Further characterization of the antithrombin-binding sequence in heparin
1982 Standout
Randomized trial of subcutaneous low-molecular-weight heparin CY 216 (Fraxiparine) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism. A dose-ranging study.
1992
Two-dimensional protein crystallization via metal-ion coordination by naturally occurring surface histidines.
1996 StandoutNobel
The antithrombin-binding sequence of heparin studied by n.m.r. spectroscopy
1981
Studies on the Mechanism of the Rate‐Enhancing Effect of Heparin on the Thrombin‐Antithrombin III Reaction
1979
Partial NH2- and cooh-terminal sequence analyses of Eco RI DNA restriction and modification enzymes.
1981 StandoutNobel
The molecular-weight dependence of the rate-enhancing effect of heparin on the inhibition of thrombin, factor Xa, factor IXa, factor XIa, factor XIIa and kallikrein by antithrombin
1981
The Unique Antithrombin III Binding Domain of Heparin: A Lead to New Synthetic Antithrombotics
1993
Interaction of single-chain urokinase-type plasminogen activator with human endothelial cells.
1990 StandoutNobel
Evidence for a 3-O-sulfated D-glucosamine residue in the antithrombin-binding sequence of heparin.
1980
Carbon nanotube–polymer composites: Chemistry, processing, mechanical and electrical properties
2009 Standout
Heparin binding properties of human histidine-rich glycoprotein. Mechanism and role in the neutralization of heparin in plasma.
1983
Comparison between commercial heparin, low molecular weight heparin and pentosan polysulfate on hemostasis and platelets in vivo
1982
Heparin with two binding sites for antithrombin or platelet factor 4.
1982
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
2015 Standout
Pathophysiological and histomorphological evaluation of polyacryloylmorpholine vs polyethylene glycol modified superoxide dismutase in a rat model of ischaemia/reperfusion injury
1996
Low-Molecular-Weight Heparins
1997 Standout
Die charakteristische AT‐III‐Bindungsregion in Heparin: eine Leitstruktur für neue synthetische Antithrombotica
1993
Stimulation by heparin of the plasmin-mediated conversion of single-chain to two-chain urokinase-type plasminogen activator
1986
Measurement of Poly(ethylene glycol) by Cell-Based Anti-poly(ethylene glycol) ELISA
2010
Preparation of highly stable antithrombin-sepharose and utilization for the fractionation of heparin
1982
Biodistribution properties of nanoparticles based on mixtures of PLGA with PLGA–PEG diblock copolymers
2005
Magnetic Nanoparticles: Design and Characterization, Toxicity and Biocompatibility, Pharmaceutical and Biomedical Applications
2012 Standout
The molecular size of the antithrombin‐binding sequence in heparin
1980
Importance of Size, Sulfation, and Anticoagulant Activity in the Potentiation of Acidic Fibroblast Growth Factor by Heparin
1989
Low Molecular Weight Heparin and Compression Stockings in the Prevention of Venous Thromboembolism in Neurosurgery
1996
Structure of the antithrombin-binding site in heparin.
1979
Dendrimers Designed for Functions: From Physical, Photophysical, and Supramolecular Properties to Applications in Sensing, Catalysis, Molecular Electronics, Photonics, and Nanomedicine
2010 Standout
Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4
1984
Functions of Cell Surface Heparan Sulfate Proteoglycans
1999 Standout
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
2014 Standout
Extension and structural variability of the antithrombin-binding sequence in heparin.
1984
Catabolism of low-dose heparin in man
1979
Fluorescence-Based Blood Coagulation Assay Device for Measuring Activated Partial Thromboplastin Time
2010 StandoutNobel
The molecular-weight-dependence of the anti-coagulant activity of heparin
1978
Physico-Chemical and Biological Properties of Monofunctional Hydroxy Teriminating Poly(N-Vinylpyrrolidone) Conjugated Superoxide Dismutase
1995
Molecular weight dependency of the heparin potentiated inhibition of thrombin and activated factor X. Effect of heparin neutralization in plasma
1979
Inorganic Nanoparticles for MRI Contrast Agents
2009 Standout
Anticoagulant effects of two types of low molecular weight heparin administered subcutaneously
1983
Role of collagenous matrices in the adhesion and growth of cells.
1981 Standout
Works of G.E.C. Sims being referenced
Large-scale preparation and biochemical characterization of a new high purity factor IX concentrate prepared by metal chelate affinity chromatography
1994
Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin III and by gel filtration
1976
A method for the estimation of polyethylene glycol in plasma protein fractions
1980